112 related articles for article (PubMed ID: 12375015)
21. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
Miyatake K; Gemba K; Ueoka H; Nishii K; Kiura K; Tabata M; Shibayama T; Takigawa N; Kawaraya M; Tanimoto M
Anticancer Res; 2003; 23(3C):2829-36. PubMed ID: 12926120
[TBL] [Abstract][Full Text] [Related]
22. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
23. Glutathione system, topoisomerase II level and multidrug resistance phenotype in acute myelogenous leukemia before treatment and at relapse.
Massaad-Massade L; Ribrag V; Marie JP; Faussat AM; Bayle C; Dreyfus F; Gouyette A
Anticancer Res; 1997; 17(6D):4647-51. PubMed ID: 9494583
[TBL] [Abstract][Full Text] [Related]
24. Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi.
Mathieu A; Remmelink M; D'Haene N; Penant S; Gaussin JF; Van Ginckel R; Darro F; Kiss R; Salmon I
Cancer; 2004 Oct; 101(8):1908-18. PubMed ID: 15386340
[TBL] [Abstract][Full Text] [Related]
25. Analysis of chemoresistance in lung cancer with a simple microfluidic device.
Zhang L; Wang J; Zhao L; Meng Q; Wang Q
Electrophoresis; 2010 Nov; 31(22):3763-70. PubMed ID: 20949633
[TBL] [Abstract][Full Text] [Related]
26. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
27. [Immunohistochemical investigation on the expression of glutathione S-transferases (GSTS) in lung cancer].
Nie KR; Li CH; Zhu YJ
Zhonghua Jie He He Hu Xi Za Zhi; 1993 Jun; 16(3):141-3, 186. PubMed ID: 8242809
[TBL] [Abstract][Full Text] [Related]
28. [Value of P-glycoprotein and glutathione S-transferase-pi as chemo-resistant indicators in ovarian cancers].
Zhang F; Qi L; Chen H
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):313-6. PubMed ID: 11783115
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
Huang J; Tan PH; Thiyagarajan J; Bay BH
Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
[TBL] [Abstract][Full Text] [Related]
30. Characterization and resistance mechanisms of cisplatin-resistant human hepatocellular carcinoma cell line.
Yang JX; Luo Y; Qiu HM; Tang WX
Saudi Med J; 2009 Jan; 30(1):35-40. PubMed ID: 19139770
[TBL] [Abstract][Full Text] [Related]
31. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-pi-specific inhibitor O1-hexadecyl-gamma-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester.
Nakajima T; Takayama T; Miyanishi K; Nobuoka A; Hayashi T; Abe T; Kato J; Sakon K; Naniwa Y; Tanabe H; Niitsu Y
J Pharmacol Exp Ther; 2003 Sep; 306(3):861-9. PubMed ID: 12805482
[TBL] [Abstract][Full Text] [Related]
32. Arsenic trioxide in the mechanism of drug resistance reversal in MCF-7/ADM cell line of human breast cancer.
Wang X; Kong L; Zhao J; Yang P
Zhonghua Zhong Liu Za Zhi; 2002 Jul; 24(4):339-43. PubMed ID: 12408759
[TBL] [Abstract][Full Text] [Related]
33. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
[TBL] [Abstract][Full Text] [Related]
34. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease.
Triller N; Korosec P; Kern I; Kosnik M; Debeljak A
Lung Cancer; 2006 Nov; 54(2):235-40. PubMed ID: 16934363
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
Schneider S; Uchida K; Brabender J; Baldus SE; Yochim J; Danenberg KD; Salonga D; Chen P; Tsao-Wei D; Groshen S; Hoelscher AH; Schneider PM; Danenberg PV
J Am Coll Surg; 2005 Mar; 200(3):336-44. PubMed ID: 15737843
[TBL] [Abstract][Full Text] [Related]
36. Role of metallothionein expression in non-small cell lung carcinomas.
Dziegiel P; Jeleń M; Muszczyńska B; Maciejczyk A; Szulc A; Podhorska-Okołów M; Cegielski M; Zabel M
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():43-5. PubMed ID: 15638370
[TBL] [Abstract][Full Text] [Related]
37. Over-expression of metallothionein predicts chemoresistance in breast cancer.
Yap X; Tan HY; Huang J; Lai Y; Yip GW; Tan PH; Bay BH
J Pathol; 2009 Mar; 217(4):563-70. PubMed ID: 19116991
[TBL] [Abstract][Full Text] [Related]
38. Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer.
Han CH; Cho JY; Moon JT; Kim HJ; Kim SK; Shin DH; Chang J; Ahn CM; Kim SK; Chang YS
Oncol Rep; 2006 Dec; 16(6):1205-10. PubMed ID: 17089038
[TBL] [Abstract][Full Text] [Related]
39. WWOX expression in different histologic types and subtypes of non-small cell lung cancer.
Donati V; Fontanini G; Dell'Omodarme M; Prati MC; Nuti S; Lucchi M; Mussi A; Fabbri M; Basolo F; Croce CM; Aqeilan RI
Clin Cancer Res; 2007 Feb; 13(3):884-91. PubMed ID: 17289881
[TBL] [Abstract][Full Text] [Related]
40. Expression of p53 and glutathione S-transferase-pi relates to clinical drug resistance in non-small cell lung cancer.
Nakanishi Y; Kawasaki M; Bai F; Takayama K; Pei XH; Takano K; Inoue K; Osaki S; Hara N; Kiyohara C
Oncology; 1999 Nov; 57(4):318-23. PubMed ID: 10575319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
